Financing Scientific Instrumentation as a Start-Up Company

By Antoinette Lowre, Manager of Business Development, LSN

Over the last several years, a record number of exciting life sciences start-ups have come online. Most of these start-up companies need scientific instrumentation to support their research. But when funds are limited, how can these companies get the instrumentation needed to hit their growth milestones?

Bold View Capital is hosting a workshop as part of the Service Provider Showcase at Digital RESI, September 13-16. The workshop will kick-off with an overview of the leasing market for start-ups. Expert panel will share their own experiences going through the leasing process and offer valuable lessons learned.

This workshop is valuable for start-up companies:

  • That rely on scientific instrumentation
  • That are pre-revenue and have limited funds to purchase instrumentation
  • For whom traditional financing is not available
  • That prefer debt financing to diluting equity

Instructors:

  • Darren Platt, President, Demetrix
  • Bryan Leavitt, Managing Partner, Fountainhead Investment Partners
  • Chad Kobold, Director of Business, Development, Bold View Capital

Join Bold View Capital on Wednesday, September 15 at 1 PM EDT. Sign up by August 6 to save on early bird rates!

Does it Work?

By Rory McCann, Marketing Manager & Conference Producer, LSN

I’ve heard a lot about RESI through the years, but does it work?

The question that comes from every fundraising executive at some point takes many forms, but this is frequently the hardest to answer. To do so requires a basic understanding of the Fundamental Facts of Fundraising, before explaining what RESI will and won’t do. While many entrepreneurs would enthusiastically jump at the promise of a partnering conference series offering low effort and high yield in terms of booking meetings with qualified investors and walking out with a term sheet or more, but reality doesn’t align with that story. Instead, reality aligns with the truths outlined below:

Fundamental Facts of Fundraising:

  1. Funding a startup into early-stage success and beyond is incredibly difficult and RESI won’t change that.
  2. Fundraising is a numbers game.
  3. Your best chances come from a good fit based on product and stage of development.
  4. There are strategies and best practices that set you up for success.
  5. You get out what you put in.

While not a silver bullet to any of the above, instead, RESI is a powerful tool that is:

  1. Designed to help early-stage entrepreneurs in life science and healthcare. That’s it. Every product, service, and resource are geared towards setting up scientific startups for success.
  2. A model that takes place five times each year with thirteen conferences, bringing in hundreds of investors and early-stage companies each time, creating many opportunities to book meetings.
  3. A connection vehicle that is designed for attendees to seek and target the best fits for their needs through its match-based partnering system.
  4. Equipped with an arsenal of resources set up for the early-stage entrepreneur to be successful in sourcing and booking well-fitting meetings, including free fundraising bootcamps, database subscriptions, branding and messaging services, one-day prep courses, and countless articles outlining best practices, marketing collateral, outreach strategies, and a four-step follow-up process.
  5. Rewarding to those who apply proven strategies and are willing to work.

No matter how expensive or high quality, a hammer will only build a house in the hands of a builder who knows how to use it and shows up to work. I recently connected with two CEOs – one had a very negative perspective of his RESI experience and one with a very positive one.

The first CEO stated that RESI was the “world’s worst meeting ever” and insinuated that he was more deserving of investors’ time with “hit my name in Google”. When I dug deeper, it was clear that he had sent roughly 15% of the meeting invitations of his counterparts with no attempt at follow-up. I’m not surprised he did not have a better experience.

The second CEO shared that he had had a very positive experience at RESI. He then outlined his pre-conference strategy in which he identified several investors who were an excellent fit for his company, and even prepared a secondary list of investors who were less of a match, but still may consider taking a meeting – which he inevitably used when an investor was unable to connect. He also detailed his post-conference follow-up strategy. He shared how he recognized the opportunity available to him and he was willing to work hard to make the most of it. While he didn’t ask me to “hit his name in Google”, I did anyway. His company raised a multi-million-dollar Series A shortly afterwards. Unsurprisingly, it says more about his ethic than whether a partnering conference “works”.

Like most things worth our time and effort, RESI is a valuable tool that will work if you do. Join us September 13-17 to see what it’s all about at the virtual RESI Partnering Week. Save when you register by August 6. We hope to see you virtually there!

Hot Investor Mandate: Hybrid Family Office Invests in Life Science Companies Across All Stage of Development, With Strong Interests in Oncology, Cardiovascular, GI, and Other Indications

A hybrid family office operating in the USA can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said, the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Firm Invests Up to $30M in Therapeutics, Diagnostics, and R&D Tools/Services, Interested in Global Opportunities

A venture capital firm based in the USA can invest anywhere from $4-30M, with $11M being the median initial check size. The firm invests in both seed and crossover rounds. While most of the current portfolio companies are USA-based, the firm has a global portfolio and is open to global investment opportunities.

The firm focuses on these 3 key areas: therapeutics, diagnostics, and R&D tools/services. The firm also considers digital health opportunities that tie in with their key areas, such as technologies enhancing R&D efficacy, drug development process, etc. The firm stirs away from medical devices (basically, all technologies that require FDA approval), including implantable devices. With regards to the firm’s main interest areas, The firm is most interested in seeing new approaches (i.e. cell & gene therapy, novel ways of manufacturing cell lines, etc). The firm will invest in both pre-clinical and clinical technologies.

The firm has no specific company or management team requirements and is open to working with management teams coming from varying levels of experience. The firm prefers to act as the lead investor, and has done so for almost all of their portfolio companies thus far. The firm is a very active, hands-on investor and will generally seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canada-Based Investment Firm Seeks Medical Devices, Diagnostics, and Digital Health Companies, Investing Up to $20M

A firm headquartered in Canada with offices worldwide manages a variety of different investment vehicles including private equity and multi-strategy funds.  In the life sciences, the firm makes equity investments typically at Series A. The firm’s minimum investment is $2M and can go up to $20M.  The firm focuses on companies based in North America but has the capacity to invest worldwide.

In the life sciences, the firm focuses on medical devices, diagnostics and digital health companies.  The firm prefers to invest in companies that are close to commercialization or which are already generating revenue (for example, device companies must ideally be ready to file for a CE Mark, 510k or Health Canada application).

The firm prefers to invest in experienced entrepreneurs who have deep knowledge of their sector. The firm only invests in companies developing products that have a clear path to market, and which serve a clear need; the firm prefers to invest in companies that are no more than a year from obtaining revenues.  As the firm has offices globally, the firm is well placed to help portfolio companies make international distribution or license/royalty agreements.  The firm invests in both public and privately-held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Actively Seeks Digital Health Technologies and Tech-Enabled Medical Devices & Diagnostic Tools, With USA Focus

A venture capital firm in the USA had its beginnings as an incubator, providing seed funding to very early-stage companies for the first two years. Since then, the firm has also branched into a venture arm that expanded the investment focus to Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Longevity Mandate: Japanese Pharma Corporate Venture Capital Fund

The firm is a $300 million strategic corporate venture capital fund by a Japanese pharma. The fund seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in USA and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to TPC’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications. While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the parent company’s established expertise in the field of oncology product discovery and development, The firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.